Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Extension Study of Adjunctive ALKS 5461 in the Treatment of Refractory Major Depressive Disorder

NCT03610048 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT03610048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03610048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Extension Study of Adjunctive ALKS 5461 in the Treatment of Refractory Major Depressive Disorder
Lead sponsor
Alkermes, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
August 9, 2018
Completion date
May 1, 2020
Enrollment
175 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

refractory major depressive disorder